An α-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients

Noriko Satoh, Akira Shimatsu, Kazunori Yamada, Megumi Aizawa-Abe, Takayoshi Suganami, Hideshi Kuzuya, Yoshihiro Ogawa

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Postprandial hyperglycemia and hyperlipidemia are considered risk factors for cardiovascular disease. This study was designed to elucidate whether improving the postprandial state by voglibose, an α-glucosidase inhibitor, leads to the reduction of oxidative stress markers and soluble adhesion molecules in obese type 2 diabetic patients. A total of 30 Japanese obese type 2 diabetic patients were randomly assigned and treated for 3 weeks with either diet alone (the control group) or diet plus voglibose (0.9 mg daily) (the voglibose group) (n = 15 each). Analysis of the diurnal metabolic profiles revealed a significant reduction of postprandial hyperglycemia and hyperlipidemia in the voglibose group relative to the control group (P < .05), despite the similar improvement in body mass index and hemoglobin A1c in both groups. Voglibose also decreased significantly the plasma levels of soluble intercellular adhesion molecule 1 and urinary excretion of 8-iso-prostaglandin F2α and 8-hydroxydeoxyguanosine (P < .01) and C-reactive protein (P < .05) relative to the control group. In conclusion, this study represents the first demonstration that voglibose reduces oxidative stress generation and soluble intercellular adhesion molecule 1 in parallel with the reduction of postprandial hyperglycemia and hyperlipidemia in obese type 2 diabetic patients.

Original languageEnglish
Pages (from-to)786-793
Number of pages8
JournalMetabolism: Clinical and Experimental
Volume55
Issue number6
DOIs
Publication statusPublished - Jun 1 2006
Externally publishedYes

Fingerprint

Glucosidases
Intercellular Adhesion Molecule-1
Oxidative Stress
Hyperlipidemias
Hyperglycemia
Control Groups
Diet
Dinoprost
Metabolome
C-Reactive Protein
voglibose
Hemoglobins
Body Mass Index
Cardiovascular Diseases

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

An α-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. / Satoh, Noriko; Shimatsu, Akira; Yamada, Kazunori; Aizawa-Abe, Megumi; Suganami, Takayoshi; Kuzuya, Hideshi; Ogawa, Yoshihiro.

In: Metabolism: Clinical and Experimental, Vol. 55, No. 6, 01.06.2006, p. 786-793.

Research output: Contribution to journalArticle

Satoh, Noriko ; Shimatsu, Akira ; Yamada, Kazunori ; Aizawa-Abe, Megumi ; Suganami, Takayoshi ; Kuzuya, Hideshi ; Ogawa, Yoshihiro. / An α-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. In: Metabolism: Clinical and Experimental. 2006 ; Vol. 55, No. 6. pp. 786-793.
@article{a0b508ffdba1412ea9269dc445d6375e,
title = "An α-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients",
abstract = "Postprandial hyperglycemia and hyperlipidemia are considered risk factors for cardiovascular disease. This study was designed to elucidate whether improving the postprandial state by voglibose, an α-glucosidase inhibitor, leads to the reduction of oxidative stress markers and soluble adhesion molecules in obese type 2 diabetic patients. A total of 30 Japanese obese type 2 diabetic patients were randomly assigned and treated for 3 weeks with either diet alone (the control group) or diet plus voglibose (0.9 mg daily) (the voglibose group) (n = 15 each). Analysis of the diurnal metabolic profiles revealed a significant reduction of postprandial hyperglycemia and hyperlipidemia in the voglibose group relative to the control group (P < .05), despite the similar improvement in body mass index and hemoglobin A1c in both groups. Voglibose also decreased significantly the plasma levels of soluble intercellular adhesion molecule 1 and urinary excretion of 8-iso-prostaglandin F2α and 8-hydroxydeoxyguanosine (P < .01) and C-reactive protein (P < .05) relative to the control group. In conclusion, this study represents the first demonstration that voglibose reduces oxidative stress generation and soluble intercellular adhesion molecule 1 in parallel with the reduction of postprandial hyperglycemia and hyperlipidemia in obese type 2 diabetic patients.",
author = "Noriko Satoh and Akira Shimatsu and Kazunori Yamada and Megumi Aizawa-Abe and Takayoshi Suganami and Hideshi Kuzuya and Yoshihiro Ogawa",
year = "2006",
month = "6",
day = "1",
doi = "10.1016/j.metabol.2006.01.016",
language = "English",
volume = "55",
pages = "786--793",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - An α-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients

AU - Satoh, Noriko

AU - Shimatsu, Akira

AU - Yamada, Kazunori

AU - Aizawa-Abe, Megumi

AU - Suganami, Takayoshi

AU - Kuzuya, Hideshi

AU - Ogawa, Yoshihiro

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Postprandial hyperglycemia and hyperlipidemia are considered risk factors for cardiovascular disease. This study was designed to elucidate whether improving the postprandial state by voglibose, an α-glucosidase inhibitor, leads to the reduction of oxidative stress markers and soluble adhesion molecules in obese type 2 diabetic patients. A total of 30 Japanese obese type 2 diabetic patients were randomly assigned and treated for 3 weeks with either diet alone (the control group) or diet plus voglibose (0.9 mg daily) (the voglibose group) (n = 15 each). Analysis of the diurnal metabolic profiles revealed a significant reduction of postprandial hyperglycemia and hyperlipidemia in the voglibose group relative to the control group (P < .05), despite the similar improvement in body mass index and hemoglobin A1c in both groups. Voglibose also decreased significantly the plasma levels of soluble intercellular adhesion molecule 1 and urinary excretion of 8-iso-prostaglandin F2α and 8-hydroxydeoxyguanosine (P < .01) and C-reactive protein (P < .05) relative to the control group. In conclusion, this study represents the first demonstration that voglibose reduces oxidative stress generation and soluble intercellular adhesion molecule 1 in parallel with the reduction of postprandial hyperglycemia and hyperlipidemia in obese type 2 diabetic patients.

AB - Postprandial hyperglycemia and hyperlipidemia are considered risk factors for cardiovascular disease. This study was designed to elucidate whether improving the postprandial state by voglibose, an α-glucosidase inhibitor, leads to the reduction of oxidative stress markers and soluble adhesion molecules in obese type 2 diabetic patients. A total of 30 Japanese obese type 2 diabetic patients were randomly assigned and treated for 3 weeks with either diet alone (the control group) or diet plus voglibose (0.9 mg daily) (the voglibose group) (n = 15 each). Analysis of the diurnal metabolic profiles revealed a significant reduction of postprandial hyperglycemia and hyperlipidemia in the voglibose group relative to the control group (P < .05), despite the similar improvement in body mass index and hemoglobin A1c in both groups. Voglibose also decreased significantly the plasma levels of soluble intercellular adhesion molecule 1 and urinary excretion of 8-iso-prostaglandin F2α and 8-hydroxydeoxyguanosine (P < .01) and C-reactive protein (P < .05) relative to the control group. In conclusion, this study represents the first demonstration that voglibose reduces oxidative stress generation and soluble intercellular adhesion molecule 1 in parallel with the reduction of postprandial hyperglycemia and hyperlipidemia in obese type 2 diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=33646518771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646518771&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2006.01.016

DO - 10.1016/j.metabol.2006.01.016

M3 - Article

C2 - 16713439

AN - SCOPUS:33646518771

VL - 55

SP - 786

EP - 793

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 6

ER -